Company Information

  

Address: 3530 JOHN HOPKINS COURT  
City: SAN DIEGO 
State: CA 
Zip Code: 92121 
Telephone: (858) 633-0300 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a pioneering clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Natural killer, or NK, cells are the body's first line of defense due to their innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or activation by other support molecules required to activate adaptive immune cells such as T-cells. We believe that our proprietary NK cell line, coupled with our planned integrated discovery ecosystem, positions us to implement precision cancer medicine by leveraging the advances that have evolved during the past decade and addressing newly discovered challenges of cancer.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.25NAN/E
12/2017-1.20NAN/E
09/2017-1.18NAN/E
06/2017-1.28NAN/E
03/2017-1.39NAN/E
12/2016-1.47NAN/E
09/2016-1.42NAN/E
06/2016-1.52NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.13Total Liab/Total Assets0.13
Net Inc/Total Assets-0.39Total Liab/Inv Cap0.14
Net Inc/Inv Cap-0.42Total Liab/Comm Equity0.04
Pretax Inc/Net Sales-2153.69Interest Coverage Ratio-155.82
Net Inc/Net Sales-2142.73Curr Debt/EquityNA
Cash Flow/Net Sales-1084.00LTD/EquityNA
SG&A/NetSales1269.36Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover0.07Quick Ratio6.35
Inventory TurnoverNACurrent Ratio6.35
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.00Inv/Curr AssetsNA
Net Sales/PP&E0.00  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.01 0.01 0.01 0.01
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 14.30 13.39 13.38 14.13
Operating Income -28.28 -25.39 -24.44 -23.82
Interest Exp 0.03 0.03 0.39 0.15
Pretax Income -27.64 -24.66 -24.07 -23.58
Other Income 0.67 0.77 0.77 0.40
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -27.52 -24.49 -23.97 -23.45

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 121.79 128.15 152.27 175.51
Receivables - Total 0.06 0.15 0.06 0.08
Inventories - Total NA NA NA NA
Total Current Assets 126.80 132.46 156.85 181.56
Net Property, Plant & Equipment 76.83 76.73 74.47 60.22
Total Assets 229.85 250.44 277.74 301.62
Liabilities        
Accounts Payable 18.10 19.50 27.31 20.87
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 19.40 20.87 28.67 36.88
Long-Term Debt NA NA NA NA
Total Liabilities 29.49 31.60 40.03 48.70
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -526.05 -498.71 -471.46 -447.49
Treasury Stock NA NA NA NA
Total Stockholders' Equity 200.36 218.84 237.70 252.92
Total Liabilities and Stockholders' Equity 229.85 250.44 277.74 301.62

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -15.51 -13.64 -10.13 -14.95
Net Cash Provided by Investing Activities 2.92 19.73 6.96 56.82
Net Cash Provided by Financing Activities -0.09 -3.14 -14.95 -16.43

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.60-2.05--
12/20140.64-6.18--
12/20150.24-236.88-3.31
12/20160.04-120.81-1.47
12/20170.04-96.42-1.20
Growth Rates-47.67----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/187111,15714.29




Report Date : 6/18/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.